Stock Worth Watching: What Next for BioCryst Pharmaceuticals, Inc. Stock After Today’s Huge Increase?

Stock Worth Watching: What Next for BioCryst Pharmaceuticals, Inc. Stock After Today's Huge Increase?

The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a huge mover today! The stock increased 3.85% or $0.17 during the last trading session, hitting $4.58. About 688,222 shares traded hands. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 121.61% since February 29, 2016 and is uptrending. It has outperformed by 109.39% the S&P500.
The move comes after 9 months positive chart setup for the $334.51M company. It was reported on Oct, 4 by Barchart.com. We have $11.50 PT which if reached, will make NASDAQ:BCRX worth $505.11M more.

Analysts await BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings on November, 3. They expect $-0.23 EPS, down 15.00% or $0.03 from last year’s $-0.2 per share. After $-0.22 actual EPS reported by BioCryst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Out of 8 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. BioCryst Pharmaceuticals has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Friday, October 9, the company rating was downgraded by Bank of America. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has “Hold” rating given on Tuesday, February 9 by Needham. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Neutral” rating by JP Morgan on Tuesday, February 9. The stock of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earned “Sell” rating by Zacks on Friday, August 7. Jefferies downgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Tuesday, February 9. Jefferies has “Buy” rating and $2 price target. The rating was maintained by FBR Capital with “Outperform” on Tuesday, February 9. Jefferies upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Wednesday, January 6 to “Buy” rating. JMP Securities downgraded the stock to “Market Perform” rating in Thursday, August 4 report. Jefferies maintained BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) rating on Friday, August 5. Jefferies has “Hold” rating and $3 price target. The company was upgraded on Friday, August 12 by PiperJaffray.

According to Zacks Investment Research, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.”

Insitutional Activity: The institutional sentiment decreased to 0.79 in Q2 2016. Its down 0.31, from 1.1 in 2016Q1. The ratio fall, as 17 funds sold all BioCryst Pharmaceuticals, Inc. shares owned while 31 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 45.48 million shares or 10.25% less from 50.68 million shares in 2016Q1.
Northeast Consultants last reported 20,000 shares in the company. Manufacturers Life Insur The holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 55,229 shares. Schwab Charles Inv Inc has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Blackrock Institutional Tru Na last reported 0% of its portfolio in the stock. Vanguard Grp Incorporated last reported 3.53 million shares in the company. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 2,912 shares. Moreover, Morgan Stanley has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 16,794 shares. Teacher Retirement Systems Of Texas reported 8,224 shares or 0% of all its holdings. New York State Common Retirement Fund last reported 69,300 shares in the company. Blackrock Ltd Liability reported 278,020 shares or 0% of all its holdings. Highbridge Cap Mgmt Ltd Llc accumulated 0.01% or 132,288 shares. Northern Tru Corporation holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 863,925 shares. Moreover, Planning Corp has 0.01% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 41,000 shares. Millennium Mgmt Limited Com, a New York-based fund reported 30,068 shares. Swiss National Bank, a Switzerland-based fund reported 96,300 shares.

Insider Transactions: Since August 9, 2016, the stock had 0 insider buys, and 5 sales for $20.50 million net activity. BAKER BROS. ADVISORS LP also sold $20.25M worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Friday, August 12. Barnes Alane P had sold 8,357 shares worth $35,684 on Wednesday, September 14. 5,864 shares were sold by STAAB THOMAS R II, worth $30,388. Babu Yarlagadda S also sold $121,800 worth of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Thursday, August 25.

More news for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) were recently published by: Fool.com, which released: “Here’s the Buzz Behind BioCryst Pharmaceuticals, Inc.’s 27% Gain in July” on August 11, 2016. Seekingalpha.com‘s article titled: “BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2016 Results …” and published on August 05, 2016 is yet another important article.

BCRX Company Profile

BioCryst Pharmaceuticals, Inc. (BioCryst), incorporated on November 15, 1991, is a biotechnology company. The Firm designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Firm focuses on the treatment of rare diseases. The Firm uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment